Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding Investigational Device Exemptions (IDE) - IDE Documentation Requirements for Studies with an FDA Approval dated January 01, 2015, or later (A54919) - R8 - Effective October 1, 2015 Jul 03, 2025
2025 Q3 MolDX CPT/HCPCS Billing and Coding Article Updates - Effective July 1, 2025 Jul 03, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R26 - Effective July 1, 2025 Jul 03, 2025
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R16 - Effective July 1, 2025 Jul 03, 2025
MolDX: Breast Cancer Index (BCI) Gene Expression Test (L37822) - R5 - Effective July 3, 2025 Jul 03, 2025
MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (L39005) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Pharmacogenomics Testing (L38335) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (L38643) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (L38327) - R3 - Effective July 3, 2025 Jul 03, 2025
MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (L38647) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38339) - R3 - Effective July 3, 2025 Jul 03, 2025
MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39001) - R4 - Effective July 3, 2025 Jul 03, 2025
MolDX Local Coverage Determinations (LCDs) Finalized - Effective August 17, 2025 Jul 03, 2025
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R21 - Effective July 1, 2025 Jul 03, 2025
Self-Administered Drug Exclusion List (A53032) - R42 - Effective July 1, 2025 Jun 26, 2025
2025 CPT/HCPCS Billing and Coding Article Updates - Effective July 1, 2025 Jun 26, 2025
Billing and Coding: MolDX: Immunohistochemistry (IHC) Indications for Breast Pathology (A57523) Retirement - Effective June 26, 2025 Jun 26, 2025
Billing and Coding: Peripheral Nerve Stimulation (A55530) - R11 - Effective June 26, 2025 Jun 26, 2025
MolDX: Melanoma Risk Stratification Molecular Testing (L37750) - R7 - Effective June 26, 2025 Jun 26, 2025
Billing and Coding: Epidural Steroid Injections for Pain Management (A58993) - R5 - Effective November 15, 2023 Jun 19, 2025
Polysomnography and Other Sleep Studies Final LCD - Effective July 20, 2025 Jun 05, 2025
Open Public Meeting Announcement - Transurethral Waterjet Ablation of the Prostate - June 26, 2025 May 29, 2025
Proposed LCD Transurethral Waterjet Ablation of the Prostate - Published for Review and Comments May 29, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R25 - Effective May 29, 2025 May 29, 2025
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A58168)- R10 - Effective November 21, 2024 May 22, 2025
Proposed LCDs - Published for Review and Comments May 15, 2025
Open Public Meeting Announcement - Multiple LCDs - June 26, 2025 May 15, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R8 - Effective February 14, 2025 May 01, 2025
Billing and Coding: Immune Globulin Intravenous (IVIg) (A57187) - R9 - Effective January 1, 2025 Apr 24, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58996) - R9 - Effective January 1, 2025 Apr 24, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R10 - February 18, 2025 Apr 24, 2025
Billing and Coding: Bariatric Surgery Coverage (A53026) - R18 - Effective October 1, 2024 Apr 24, 2025
Billing and Coding: Billing Limitations for Pharmacies (A56119) - R10 - Effective January 1, 2025 Apr 24, 2025
Self-Administered Drug Exclusion List (A53032) - R41- Effective June 1, 2025 Apr 17, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R7 - Effective April 17, 2025 Apr 17, 2025
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R20 - Effective April 1, 2025 Apr 11, 2025
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A58168) - R9 - Effective April 1, 2025 Apr 04, 2025
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R22 - Effective April 1, 2025 Apr 04, 2025
Billing and Coding: MolDX: Proteomics Testing (A59641) - R8 - Effective April 1, 2025 Apr 04, 2025
Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R7 - Effective April 1, 2025 Apr 04, 2025
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R16 - Effective April 1, 2025 Apr 04, 2025
Billing and Coding: Leadless Pacemakers (A59819) - R3 - Effective October 08, 2024 Apr 03, 2025
April 2025 CPT/HCPCS Billing and Coding Article Updates Mar 28, 2025
Billing and Coding: Epidural Steroid Injections for Pain Management (A58993) - R4 - Effective June 19, 2022 Mar 20, 2025
Billing and Coding: Guardant360® (A58192) Retirement - Effective December 25, 2022 Mar 17, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720)- R24- Effective March 13, 2025 Mar 14, 2025
MolDX: Prometheus IBD sgi Diagnostic Policy (L37299) - R8 - Effective March 13, 2025 Mar 14, 2025
MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules (L39682) - R1 - Effective March 13, 2025 Mar 14, 2025
MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia (L39262) - R1 - Effective March 13, 2025 Mar 14, 2025
MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L39230) - R1 - Effective March 6, 2025 Mar 07, 2025